Loqtorzi
Jun 03, 2024
Rapid Global Expansion of Chinese PD-1/PD-L1 Key Players
Immune checkpoint inhibitors (ICIs) are currently among the most widely used treatments for cancer. Chinese pharmaceutical companies have been making significant strides in developing PD-1 and PD-L1 inhibitors, used to treat various cancers. Several of these companies are now entering or planning to enter the US an...
Read More...
May 31, 2024
The Journey of PD-(L)1 Inhibitors: Milestones and Breakthroughs
The advent of PD-(L)1 inhibitors marks a monumental shift in the landscape of cancer treatment. These agents have redefined the therapeutic approach to several malignancies, offering hope where traditional therapies often fell short. PD-(L)1 inhibitors are a class of drugs that block the interaction between the pro...
Read More...
Nov 06, 2023
Coherus and Junshi’s Loqtorzi: First-ever Chinese PD-1 Inhibitor and Nasopharyngeal Carcinoma Treatment
On 27 October 2023, Coherus BioSciences and Shanghai Junshi Biosciences received FDA approval for Loqtorzi (toripalimab), marking a significant milestone as the first-ever sanctioned treatment for nasopharyngeal carcinoma. The medication has gained approval for use alongside cisplatin and gemcitabine as an initial ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
